DBV Technologies (NASDAQ:DBVT) Rating Increased to Sell at The Goldman Sachs Group

DBV Technologies (NASDAQ:DBVT - Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a "sell" rating in a research report issued on Thursday, Marketbeat Ratings reports. The firm currently has a $7.25 price target on the stock. The Goldman Sachs Group's price objective would indicate a potential downside of 12.65% from the company's previous close.

A number of other equities research analysts have also weighed in on DBVT. JMP Securities lifted their target price on DBV Technologies from $15.00 to $21.00 and gave the company a "market outperform" rating in a research report on Tuesday. HC Wainwright lifted their target price on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. Finally, Wall Street Zen raised DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, DBV Technologies currently has an average rating of "Hold" and an average target price of $14.75.

DBV Technologies Stock Performance

NASDAQ DBVT traded down $0.51 on Thursday, reaching $8.30. 47,266 shares of the stock traded hands, compared to its average volume of 191,150. The company has a fifty day moving average price of $8.44 and a 200-day moving average price of $5.48. The company has a market cap of $227.34 million, a price-to-earnings ratio of -1.84 and a beta of -0.66. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, research analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. Institutional investors own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.